Skip to content

Dose-response study of OPC-12759 ophthalmic suspension

Dose-response study of OPC-12759 ophthalmic suspension

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220040
Enrollment
Unknown
Registered
2005-09-06
Start date
2005-09-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye

Interventions

Sponsors

Otsuka Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria 1. Males or females; 2. Out patient; 3. 20 years of age or older; 4. Subjective complaint of dry eye that has been present for minimum 20 months; 5. Primary ocular discomfort severity is moderate to severe; 6. Corneal - conjunctival damage is moderate to severe; 7. Unanesthetized Schirmer's test score of 7mm/5minutes or less; 8. Best corrected visual acuity of 0.2 or better in both eyes. Exclusion criteria 1. Presence of anterior segment disease or disorder other than that associated with keratoconjuntivitis sicca; 2. Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study; 3. Anticipated use of contact lens during the study; 4. Any history of ocular surgery within 12 months ; 5. Female patients who are pregnant, possibly pregnant or breast feeding; 6. Known hypersensitivity to any component of the study drug or procedual medications; 7. Receipt of any investigational product within 4 months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy, Safety

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026